In human epidermal growth factor receptor 2 (HER2)+ breast cancer, epigenetic alteration of m6A hypomethylation causes FGFR4 to phosphorylate GSK3β and then activate the β‐catenin/transcription factor 4 signaling pathway, leading to anti‐HER2 therapeutics in tumor cells.296. Here, ERBB2 is linked to breast carcinoma.